MBD-seq - realities of a misunderstood method for high-quality methylome-wide association studies.
Epigenetics
; 15(4): 431-438, 2020 04.
Article
em En
| MEDLINE
| ID: mdl-31739727
ABSTRACT
The majority of methylome-wide association studies (MWAS) have been performed using commercially available array-based technologies such as the Infinium Human Methylation 450K and the Infinium MethylationEPIC arrays (Illumina). While these arrays offer a convenient and relatively robust assessment of the probed sites they only allow interrogation of 2-4% of all CpG sites in the human genome. Methyl-binding domain sequencing (MBD-seq) is an alternative approach for MWAS that provides near-complete coverage of the methylome at similar costs as the array-based technologies. However, despite publication of multiple positive evaluations, the use of MBD-seq for MWAS is often fiercely criticized. Here we discuss key features of the method and debunk misconceptions using empirical data. We conclude that MBD-seq represents an excellent approach for large-scale MWAS and that increased utilization is likely to result in more discoveries, advance biological knowledge, and expedite the clinical translation of methylome-wide research findings.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Análise de Sequência de DNA
/
Estudo de Associação Genômica Ampla
/
Epigenômica
/
Epigenoma
Tipo de estudo:
Diagnostic_studies
/
Evaluation_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Epigenetics
Assunto da revista:
GENETICA
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Estados Unidos